Galmed Pharmaceuticals to execute 1-for-8 reverse share split Aug. 19, 2026
GLMD•Reverse share split details
- Galmed Pharmaceuticals will execute a 1-for-8 reverse share split of its ordinary shares.
- Post-split trading on the Nasdaq Capital Market is set to begin on Aug. 19, 2026.
- Issued and outstanding shares are expected to fall to about 1,041,565 from 8,332,518, subject to fractional-share treatment.
- Authorized share capital will be 112,500,000 ordinary shares with par value NIS 14.40 per share.
- Outstanding warrants and options will be adjusted proportionately; the new CUSIP for the ordinary shares will be M47238205.
